71 results about "Glycemic management" patented technology

The invention relates to the technical field of medical care informatization, in particular to a diabetes and early-stage patient self-management system based on AI and CGM, which comprises the following steps: carrying out delayed alignment on CGM blood glucose flow and multi-modal physiological signals through a signal acquisition and synchronization module; an intelligent event triggering module is used for dynamically adjusting a triggering threshold value for different disease course stages so as to identify suspected events; a mixed consistency verification engine is combined with a medical prior rule and an ensemble classification model to carry out joint discrimination, and a consistency probability is output; and the individual parameters are optimized in cooperation with a hierarchical decision-making mechanism of the interaction module and online incremental learning of the adaptive learning module. Therefore, frequent false alarms caused by physical limitations such as inherent physiological delay and signal drifting of a CGM sensor and alarm fatigue and decline of compliance of a patient caused by the frequent false alarms are solved, and more stable and personalized dynamic blood glucose management support is provided for active people in the early stage of diabetes mellitus and the like.

The invention relates to the technical field of intelligent medical monitoring, and discloses a critical patient blood glucose monitoring and risk intervention system based on artificial intelligence. The system comprises a multi-source physiological data integration module, a risk map construction module, an intervention decision generation module and an intervention execution control module. The system integrates and standardizes physiological data from the continuous blood glucose monitor and the multi-parameter monitoring equipment; the physiological parameters are mapped into pathological nodes based on the medical knowledge map, and the activation probability of the pathological nodes is calculated to construct an individualized risk map, so that systematic risk assessment is realized. Further, in combination with individual information of the patient, performing multi-objective optimization on the intervention strategy by applying a simulated annealing algorithm to generate an optimal decision; and analyzing the decision into a control instruction to drive the insulin pump to execute precise intervention. According to the invention, the crossing from passive alarm to active risk prediction and personalized intervention is realized, and the safety and accuracy of blood glucose management of critical patients are improved.

The present application relates to a terminal device for blood sugar management during pregnancy and its cloud server, the terminal device collects physiological data and blood sugar data of a target user including the gestation period, the cloud server obtains a plurality of blood sugar data of reference users from a plurality of terminal devices and forms an overall reference data set in a manner associated with gestational age, the cloud server calculates basic statistical indicators for each group in the overall reference data set, combines the specific percentile position of the user's blood sugar data in its own group distribution, judges the current blood sugar state of the user by comparing the user's blood sugar data with the preset healthy blood sugar range, and generates a graded diet suggestion accordingly, the diet suggestion optimizes the diet structure of the target user by selecting food categories with different GI values; the terminal device receives and visually displays personalized diet suggestions matching the blood sugar status of the target user to the target user.

The application discloses a blood sugar management applet with home support function. A data acquisition interaction module is connected with an external blood glucose meter device through a Bluetooth communication protocol to collect blood sugar data of a user in real time; a home collaborative management module realizes safe sharing of blood sugar data of the user among family members, and the family members can check relevant blood sugar data, diet and exercise records through the applet end; and an intelligent analysis and reminding module is based on an LSTM neural network model, performs trend analysis on historical blood sugar data after a risk early warning trigger, generates personalized health reminding information automatically in combination with preset rules, and sends the information to the user and associated family members in a multi-modal form. The application effectively improves the blood sugar management efficiency of patients, reduces the risk of data leakage, and can significantly reduce the fasting blood sugar value and the 2-hour postprandial blood sugar value of patients compared with the prior art, reduces the cost of manual intervention, and has significant clinical application value and social and economic benefits.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to the technical field of intelligent diabetes treatment instruments, in particular to a closed-loop non-invasive insulin detection and precise infusion system which is characterized by comprising a blood glucose monitoring regulator, a non-invasive injector and a closed-loop control mechanism. The closed-loop control mechanism comprises a real-time blood glucose detection module, a temperature detection module, a blood glucose data processing module, a dose decision module, an injection pressure adjusting module, an injection channel control module, an insulin injection module and a closed-loop feedback module; noninvasive and high-sensitivity real-time blood glucose monitoring is achieved, the accuracy and timeliness of insulin administration are improved through trend prediction and individualized dose decision, meanwhile, multi-nozzle array piezoelectric needleless injection is combined with temperature compensation pressure regulation and a closed loop feedback correction mechanism, local tissue burden is effectively reduced, and the insulin administration efficiency is improved. And through multiple safety protection and wireless data transmission, remote monitoring and intelligent management are realized, so that the convenience, accuracy and reliability of blood glucose management of diabetic patients are greatly improved.

The present application relates to a blood sugar management system for pregnancy, comprising terminal devices carried by target users and reference users and a cloud server in data connection with the terminal devices, the cloud server being configured to: acquire physiological data and blood sugar data of the target users from the terminal devices, and calculate characteristic indexes of the target users based on the physiological data and the blood sugar data; acquire a plurality of blood sugar data of the reference users from the terminal devices and form an overall reference data set in a manner associated with gestational weeks, and assign the target users to a predetermined characteristic index value interval in the overall reference data set based on the characteristic indexes, so as to provide personalized health management suggestions for the target users based on factors identified to affect the risk of gestational diabetes mellitus of the target users.

The invention discloses a blood glucose management system used in a hospital, which comprises at least one blood glucose monitoring device comprising a sensor and an emitter, the sensor is used for monitoring blood glucose data of a patient in real time, and the emitter is used for at least emitting blood glucose data information; a plurality of receivers, wherein any one of the plurality of receivers can be used for receiving and transferring the information transmitted by the transmitter; the central server comprises a memory and a communication interface and is used for communicating with external equipment and storing information from the external equipment; and the medical personnel use end equipment is used for communicating with the central server and displaying or checking the blood glucose data information. Due to the fact that any one of the receivers can receive the blood glucose data monitored by the blood glucose monitoring device and upload the blood glucose data to the central server, the activity range of a patient in a hospital is not limited any more, and meanwhile medical staff can conveniently know the blood glucose level of the patient in time and in real time.

A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The present application relates to a kind of based on blood glucose biosensor pregnancy auxiliary system, belong to medical management technical field, especially, it is related to the extended application of biosensor.The system includes: a plurality of user terminals, for obtaining the data information related to user pregnancy, including the blood glucose data obtained based on blood glucose biosensor and the basic information entered;With the communication connection of user terminal server, wherein, the shared database of server construction can be divided into several subgroups based on the preset group division rule, so that each user can be based on its basic information and correspond to one subgroup in the server, the processed blood glucose data obtained by user in current gestation period can be compared with the processed blood glucose data obtained by other users in the same gestation period in corresponding subgroup, to analyze the current blood glucose management of the patient by determining the ranking way, wherein, server can determine the preset group division rule based on the category of basic information.

This invention relates to the field of clinical medical and nursing device technology, specifically to an auxiliary turntable for blood glucose management and insulin dose adjustment in critically ill patients. It includes a base and a recommendation component. A support column is fixedly connected to the top of the base. The recommendation component includes a recommendation disc fitted outside the support column. A judgment component, including a judgment disc fitted outside the support column, is fitted outside the support column and is located on top of the recommendation cover. An identification component, including an identification disc fitted outside the support column, is fitted outside the support column. A base component, including a base disc fitted outside the support column, is located on top of the identification cover. Through the base, support column, and four sets of adjustment components, standardized and visual matching of multiple blood glucose indicators and insulin adjustment recommendations is achieved. Combined with three-color risk label strips, it quickly identifies abnormal blood glucose levels and fluctuation risks, enabling early detection and intervention, and reducing dose adjustment errors due to experience.

The fluid conveying equipment comprises a medicine storage device, a rotating sleeve, a ratchet wheel, a ratchet wheel transmission part and a power assembly, and a piston rod of the medicine storage device is sleeved with the rotating sleeve in a threaded connection mode; the ratchet wheel is mounted on the rotating sleeve in a circumferential limiting manner; the ratchet wheel transmission part is elastically clamped on the tooth surface of the ratchet wheel; the power assembly is in transmission connection with the ratchet transmission part; wherein the power assembly has a first working mode and a second working mode for continuous operation, and in the first working mode, the power assembly drives the ratchet wheel transmission part to perform first movement and is in linkage with the ratchet wheel to rotate by a first angle in the preset direction; in the second working mode, the power assembly drives the ratchet wheel transmission part to conduct second movement and is in linkage with the ratchet wheel to rotate by a second angle in the preset direction. In this way, the structure of the fluid conveying equipment can be simplified, the size is reduced, and the control precision and reliability of the fluid conveying equipment during working are improved.

This invention relates to healthcare information processing technology and discloses an intelligent blood glucose management system for early warning and intervention of gestational diabetes mellitus. The system includes a data acquisition unit, a parameter mapping unit, and a state prediction unit. The data acquisition unit acquires gene polymorphism characteristic parameters and a continuous real-time blood glucose monitoring signal stream. The parameter mapping unit maps the characteristic parameters to the initial state transition matrix of the blood glucose prediction model and determines the process noise covariance matrix. The state prediction unit generates a blood glucose prediction trajectory, calculates the sliding variance of the residual sequence, and triggers covariance adaptive adjustment logic when the sliding variance continuously exceeds a preset threshold. By increasing the diagonal elements of the noise covariance matrix, the blood glucose prediction trajectory is corrected. This invention utilizes a statistically driven adaptive adjustment mechanism to effectively map the nonlinear evolution of the mother's physiological state, eliminate the mismatch between genetic priors and real-time monitoring data, and suppress false positive alarms.

The application relates to a cooking control method, a cooking control device and an automatic cooking equipment, and belongs to the technical field of cooking control. The method is applied to the automatic cooking equipment and comprises the following steps: acquiring real-time blood glucose data collected by a continuous blood glucose monitoring device; based on the real-time blood glucose data, adjusting a cooking parameter of the automatic cooking equipment from a preset cooking parameter to a first cooking parameter; determining a predicted blood glucose change rate and an actual blood glucose change rate of the real-time blood glucose data; in response to an error between the actual blood glucose change rate and the predicted blood glucose change rate corresponding to the same time period exceeding a preset threshold, adjusting the cooking parameter of the automatic cooking equipment from the first cooking parameter to a second cooking parameter based on the error. The above method can automatically adjust the cooking parameter according to the real-time blood glucose data of a user and the blood glucose change rate of the real-time blood glucose data, accurately control the glycemic index of cooked food, adapt to the blood glucose condition of the user, and meet the blood glucose management demand of the user.

The invention belongs to the technical field of functional foods and biological medicines, and particularly relates to a pea starch-polyphenol compound as well as a preparation method and application thereof. The raw materials of the pea starch-polyphenol compound comprise the following components in parts by weight: 0.8 to 1.2 parts of pea starch and 0.05 to 0.15 part of polyphenol; the polyphenol comprises at least one of the following components: quercetin, gallic acid and procyanidine. According to the invention, the pea starch is compounded with three polyphenols with different polarities, namely anthocyanin, gallic acid and quercetin, so that the pea starch-quercetin compound shows the most excellent performance: the content of resistant starch can be remarkably increased, and a V-shaped crystal structure is formed; the polypeptide disclosed by the invention shows good blood sugar regulation and intestinal flora regulation functions in vitro and in vivo, can be used for developing functional foods with low glycemic index, assists in blood sugar management of patients with type 2 diabetes, and provides an important basis for developing functional foods and medicines.

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

The invention discloses a blood glucose management system for establishing wireless communication connection by combining time and signal intensity, a signal intensity threshold value and a time threshold value are preset in the blood glucose management system, timing is carried out during the process that a patient operates to establish the wireless communication connection, and a program module searches for nearby broadcast signals and identifies the signal intensity of the broadcast signals; if the broadcast signal of which the intensity is not less than the preset signal intensity threshold value is searched within the time threshold value, the program module can establish wireless communication connection with the detection module and / or the infusion module which send the broadcast signal without inputting an equipment identifier, otherwise, the program module can establish wireless communication connection with the detection module and / or the infusion module which send the broadcast signal. If the program module does not establish the wireless communication connection with the detection module and / or the infusion module within the time threshold, the patient can input the equipment identifier in the program module to establish the wireless communication connection, so that the reliability of establishing the wireless communication connection between the program module and the detection module and / or the infusion module of the patient is ensured.

The invention discloses a hyriopsis cumingii hypoglycemic polypeptide and application thereof. The amino acid sequence of the hyriopsis cumingii hypoglycemic polypeptide is as shown in SEQ ID NO.01. The IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to alpha-glucosidase is 0.293 mmol / L, the IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to dipeptidyl peptidase-IV is 34.78 mu mol / L, postprandial blood sugar rise can be effectively inhibited, insulin secretion is promoted, and the hyriopsis cumingii hypoglycemic polypeptide is suitable for adjuvant therapy and blood sugar management of type II diabetes patients.

Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in a monitoring module and / or an infusion module; during a period when the monitoring module and / or the infusion module is powered on and sends a broadcast signal to the outside, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal and the preset signal strength threshold carried therein; when the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and / or the infusion module that sends the broadcast signal, without requiring the input of a device identifier of the monitoring module and / or the infusion module. Thus, the reliability of establishing a wireless communication connection between the program module and the patient's own monitoring module and / or infusion module is ensured.

A blood glucose management system is disclosed that incorporates a blood glucose prediction model configured to predict future blood glucose measurements of a person, such as a person with diabetes, on the basis of historical blood glucose measurements, insulin bolus dosage data, and carbohydrate intake data. The historical data are pre-processed to obtain a set of features that are advantageous for predicting future blood glucose measurements using the blood glucose prediction model. The predicted future blood glucose measurements enable the blood glucose management system to provide easy-to-understand visualizations of health information. The predicted future blood glucose measurements also enable the blood glucose management system to provide early warnings of a hypoglycemic condition or hyperglycemic condition of the person.

Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and / or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.

The present invention discloses a fuzzy control method for insulin dosage integrating emotional and motion information, belonging to the technical field of diabetes insulin treatment, which comprises the following steps: S1, estimating the emotional state and exercise intensity; S2, calculating the current insulin dosage; S3, determining the structure of the fuzzy controller, defining the input-output fuzzy distribution with the emotional state and exercise intensity information as inputs and the insulin dosage adjustment step as the output, and calculating the membership degrees of the inputs with respect to different fuzzy subsets; S4, establishing fuzzy rules; S5, performing fuzzy logic reasoning to obtain the output of the fuzzy system, and multiplying the output by the insulin dosage obtained in step S2 to determine the final insulin dosage. By adopting the above-mentioned fuzzy control method for insulin dosage integrating emotional and motion information, the present invention can achieve a more personalized and dynamic insulin administration strategy, make a more reasonable decision on the insulin dosage, and improve the blood glucose management effect of patients.

One embodiment of the present disclosure provides a method for supporting blood glucose management of a subject using a computer system, the computer system comprising a processor and a communication unit that is connected to the processor and is capable of communicating with an electronic terminal accessible by the subject, wherein the method includes: the processor acquiring, via the communication unit, GP [i] and GP [j], which are glycation rates (GP values) of a target protein of the subject at two time points t [i] and t [j] > t [i]; the processor obtaining, on the basis of GP [i] and GP [j], a glucose management index (GMI [i, j]), which is an average blood glucose level converted to a GP value for the period between the two time points t [i] and t [j]; and the processor generating output information based on the glucose management index (GMI [i, j]) and outputting the output information to the subject via the communication unit.

Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and / or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and / or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and / or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and / or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and / or infusion module.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

This invention relates to nutritional compositions comprising at least one fucosylated oligosaccharide, preferably 2FL, for use in enhancing pancreatic development and / or pancreatic maturation in infants, and / or improving insulin biosynthesis, and / or preventing metabolic disorders or associated diseases, and / or managing glucose during nutritional intervention or later in life. The composition may be an infant formula. The composition may also comprise at least one N-acetylated oligosaccharide, preferably LnNT.

This invention belongs to the technical field of functional foods for blood glucose management, specifically relating to a postprandial blood glucose-suppressing composition containing inactivated Akkermansia myxophilus. Existing blood glucose control products have limited effectiveness or significant side effects. The composition of this invention contains inactivated Akkermansia myxophilus and blood glucose-lowering active ingredients such as mulberry leaf extract and chromium yeast. This invention achieves the effects of reducing postprandial blood glucose peaks and improving glucose metabolism through a dual mechanism of slowing carbohydrate absorption and improving insulin sensitivity. The composition of this invention is stable at room temperature and can be formulated into tablets or capsules.

This invention discloses a sports nutrition food for post-exercise recovery and blood glucose management. Each 40g portion contains Astragalus membranaceus extract, Dioscorea opposita extract, white kidney bean extract, mulberry leaf extract, L-arabinose, cinnamon extract, whey protein peptides, and a mineral-vitamin-probiotic premix. This invention utilizes a six-fold blood glucose control pathway through a four-mineral glucose control matrix, triple carbohydrate blocking, probiotics, and dual tonification of Qi and Yin with traditional Chinese medicine. Animal experiments showed that the fasting blood glucose level in the full-formula group decreased to 6.3 mmol / L, significantly better than the control group (*p*<0.05). All ingredients comply with national standards for sports nutrition foods and are safe and compliant.